- Home
- ESQ vs GHRS Comparison
ESQ vs GHRS Comparison
Compare ESQ & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ESQ | GHRS |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.0M | 947.2M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ESQ | GHRS |
|---|---|---|
| Price | $115.73 | $21.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $120.33 | $41.38 |
| AVG Volume (30 Days) | 100.9K | ★ 120.6K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.69% | N/A |
| EPS Growth | ★ 14.20 | N/A |
| EPS | ★ 5.87 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.65 | N/A |
| Revenue Next Year | $4.95 | N/A |
| P/E Ratio | $19.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $78.93 | $8.75 |
| 52 Week High | $119.86 | $19.51 |
Technical Indicators
Market Signals| Indicator | ESQ | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 59.77 | 81.31 |
| Support Level | $92.21 | $12.44 |
| Resistance Level | $118.39 | N/A |
| Average True Range (ATR) | 3.68 | 1.18 |
| MACD | 0.36 | 0.64 |
| Stochastic Oscillator | 73.87 | 71.90 |
Price Performance
Historical ComparisonAbout ESQ Esquire Financial Holdings Inc.
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.